Mavoglurant as a treatment for Parkinson’s disease

Bibliography

• Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol 2013;74:337-47
   PubMed Web of Science ®Google Scholar
• Garbayo E, Ansorena E, Blanco-Prieto MJ. Drug development in Parkinson’s disease: from emerging molecules to innovative drug delivery systems. Maturitas 2013;76:272-8
   PubMed Web of Science ®Google Scholar
• Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Rasagiline in Parkinson’s disease: a review based on meta-analysis of clinical data. Pharmacol Res 2013;74:78-86
   PubMed Web of Science ®Google Scholar
• Zhuang X, Mazzoni P, Kang UJ. The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nat Rev Neurol 2013;9:248-56
   PubMed Web of Science ®Google Scholar
• Huot P, Johnston TH, Koprich JB, et al. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev 2013;65:171-222
   PubMed Web of Science ®Google Scholar
• Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci 2010;60-5
   PubMed Web of Science ®Google Scholar
• Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-75
   PubMed Web of Science ®Google Scholar
• Arbuthnott G, Garcia-Munoz M. Dealing with the devil in the detail - some thoughts about the next model of the basal ganglia. Parkinsonism Relat Disord 2009;15(Suppl 3):S139-42
   PubMedGoogle Scholar
• Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson’s disease. Prog Neurobiol 2012;96:69-86
   PubMed Web of Science ®Google Scholar
• Gardoni F, Ghiglieri V, Luca Md, Calabresi P. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson’s disease. Prog Brain Res 2010;183:169-82
   PubMed Web of Science ®Google Scholar
• Chase TN, Bibbiani F. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003;5:139-46
   PubMed Web of Science ®Google Scholar
• Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 2009;8:475-91
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG, Kornhuber J, et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents – preclinical studies. Neurosci Biobehav Rev 1997;21:455-68
   PubMed Web of Science ®Google Scholar
• Nutt JG, Gunzler SA, Kirchhoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 2008;23:1860-6
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Allard P, Grégoire L, et al. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-93
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89
   PubMed Web of Science ®Google Scholar
• Rocher JP, Bonnet B, Boléa C, et al. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutic agents. Curr Top Med Chem 2011;11:680-95
   PubMed Web of Science ®Google Scholar
• Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;315:711-21
   PubMed Web of Science ®Google Scholar
• Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009;25:2977-87
   PubMed Web of Science ®Google Scholar
• Ferrari-Toninelli G, Maccarinelli G, Uberti D, et al. Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. BMC Pharmacol 2010;10:2
   PubMedGoogle Scholar
• de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson’s disease: problems and limitations. Parkinsonism Relat Disord 2010;16:365-9
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Taylor DC. Protection against Parkinson’s disease progression: clinical experience. Neurotherapeutics 2008;5:210-25
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs 2012;72:643-69
   PubMed Web of Science ®Google Scholar
• Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 2011;25:1061-71
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 2013;13:671-84
   PubMed Web of Science ®Google Scholar
• Bartl J, Müller T, Grünblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm 2014;121:379-83
   PubMed Web of Science ®Google Scholar
• Lew MF. The evidence for disease modification in Parkinson’s disease. Int J Neurosci 2011;121(Suppl 2):18-26
   PubMedGoogle Scholar
• Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord 2013;28:131-44
   PubMed Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener 2012;1:10
   PubMedGoogle Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10:415-23
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268-78. Erratum in N Engl J Med 2011;364:1882
   PubMed Web of Science ®Google Scholar
• Boll MC, Alcaraz-Zubeldia M, Rios C. Medical management of Parkinson’s disease: focus on neuroprotection. Curr Neuropharmacol 2011;9:350-69
   PubMed Web of Science ®Google Scholar
• Orsucci D, Mancuso M, Ienco EC, et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem 2011;18:4053-64
   PubMed Web of Science ®Google Scholar
• Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81
   PubMed Web of Science ®Google Scholar
• Guigoni C, Doudnikoff E, Li Q, et al. Altered D (1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 2007;26:452-63
   PubMed Web of Science ®Google Scholar
• Blanchet P, Bedard P, Britton D, et al. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. J Pharmacol Exp Ther 1993;267:275-9
   PubMed Web of Science ®Google Scholar
• Lundblad M, Usiello A, Carta M, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005;194:66-75
   PubMed Web of Science ®Google Scholar
• Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion versus oral tablets. Br J Clin Pharmacol 2014, doi:10.1111/bcp.12324
   Google Scholar
• Johnston TH, Huot P, Fox SH, et al. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 2013;73:337-47
   PubMed Web of Science ®Google Scholar
• Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol Dis 1999;6:461-74
   PubMed Web of Science ®Google Scholar
• Cenci M, Tranberg A, Andersson M, Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment. Neuroscience 1999;94:515-27
   PubMed Web of Science ®Google Scholar
• Berton O, Guigoni C, Li Q, et al. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 2009;66:554-61
   PubMed Web of Science ®Google Scholar
• Tekumalla PK, Calon F, Rahman Z, et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson’s disease. Biol Psychiatry 2001;50:813-16
   PubMed Web of Science ®Google Scholar
• Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62
   PubMed Web of Science ®Google Scholar
• Grégoire L, Samadi P, Graham J, et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009;15:445-52
   PubMed Web of Science ®Google Scholar
• Matsubara K, Shimizu K, Suno M, et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 2006;1112:126-33
   PubMed Web of Science ®Google Scholar
• Bezard E, Tronci E, Pioli EY, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013;28:1088-96
   PubMed Web of Science ®Google Scholar
• Bird MK, Lawrence AJ. The promiscuous mGlu5 receptor – a range of partners for therapeutic possibilities? Trends Pharmacol Sci 2009;30:617-23
   PubMed Web of Science ®Google Scholar
• Valenti O, Marino MJ, Wittmann M, et al. Group III metabotropic glutamate receptor-mediated modulation of the striato pallidal synapse. J Neurosci 2003;23:7218-26
   PubMed Web of Science ®Google Scholar
• Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson’s disease. Ann Neurol 2001;49:525-9
   PubMed Web of Science ®Google Scholar
• Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010;50:295-322
   PubMed Web of Science ®Google Scholar
• Dickerson JW, Conn PJ. Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson’s disease. Neurodegener Dis Manag 2012;2:221-32
   PubMedGoogle Scholar
• Gregory KJ, Dong EN, Meiler J, Conn PJ. Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 2011;60:66-81
   PubMed Web of Science ®Google Scholar
• Ismayilova N, Verkhratsky A, Dascombe MJ. Changes in mGlu5 receptor expression in the basal ganglia of reserpinised rats. Eur J Pharmacol 2006;545:134-41
   PubMed Web of Science ®Google Scholar
• Chaki S, Ago Y, Palucha-Paniewiera A, et al. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013;66:40-52
   PubMed Web of Science ®Google Scholar
• Newell KA. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs. Future Med Chem 2013;5:1471-4
   PubMed Web of Science ®Google Scholar
• Kachroo A, Orlando LR, Grandy DK, et al. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 2005;25:10414-19
   PubMed Web of Science ®Google Scholar
• Homayoun H, Stefani MR, Adams BW, et al. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004;29:1259-69
   PubMed Web of Science ®Google Scholar
• Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007;62:739-46
   PubMed Web of Science ®Google Scholar
• Pisani A, Gubellini P, Bonsi P, et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 2001;106:579-87
   PubMed Web of Science ®Google Scholar
• Um JW, Kaufman AC, Kostylev M, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013;79:887-902
   PubMed Web of Science ®Google Scholar
• Romano C, Sesma MA, McDonald CT, et al. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995;355:455-69
   PubMed Web of Science ®Google Scholar
• Malherbe P, Kew JN, Richards JG, et al. Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Brain Res Mol Brain Res 2002;109:168-78
   PubMedGoogle Scholar
• Romano C, Smout S, Miller JK, O’Malley KL. Developmental regulation of metabotropic glutamate receptor 5b protein in rodent brain. Neuroscience 2002;111:693-8
   PubMed Web of Science ®Google Scholar
• Thomas LS, Jane DE, Harris JR, Croucher MJ. Metabotropic glutamate autoreceptors of the mGlu5 subtype positively modulate neuronal glutamate release in the rat forebrain in vitro. Neuropharmacology 2000;39:1554-66
   PubMed Web of Science ®Google Scholar
• Vallano A, Fernandez-Duenas V, Garcia-Negredo G. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson’s disease: bridging molecular studies and clinical trials. CNS Neurol Disord Drug Targets 2013;12:1128-42
   PubMed Web of Science ®Google Scholar
• Domin H, Zięba B, Gołembiowska K, et al. Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus. Pharmacol Rep 2010;62:1051-61
   PubMed Web of Science ®Google Scholar
• Jesse CR, Savegnago L, Rocha JB, Nogueira CW. Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats. Brain Res 2008;1198:197-203
   PubMed Web of Science ®Google Scholar
• Popoli P, Pintor A, Tebano MT, et al. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J Neurochem 2004;89:1479-89
   PubMed Web of Science ®Google Scholar
• Battaglia G, Fornai F, Busceti CL, et al. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J Neurosci 2002;22:2135-41
   PubMed Web of Science ®Google Scholar
• Bruno V, Ksiazek I, Battaglia G, et al. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective. Neuropharmacology 2000;39:2223-30
   PubMed Web of Science ®Google Scholar
• Brown RM, Stagnitti MR, Duncan JR, et al. The mGlu5 receptor antagonist MTEP attenuates opiate self-administration and cue-induced opiate-seeking behaviour in mice. Drug Alcohol Depend 2012;123:264-8
   PubMed Web of Science ®Google Scholar
• Ossowska K, Konieczny J, Wolfarth S, Pilc A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 2005;49:447-55
   PubMed Web of Science ®Google Scholar
• Emmitte KA. mGlu5 negative allosteric modulators: a patent review (2010-2012). Expert Opin Ther Pat 2013;23:393-408
   PubMed Web of Science ®Google Scholar
• Samadi P, Grégoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2008;29:1040-51
   PubMed Web of Science ®Google Scholar
• Breysse N, Baunez C, Spooren W, et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002;22:5669-78
   PubMed Web of Science ®Google Scholar
• Vernon AC, Zbarsky V, Datla KP, et al. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem 2007;103:1075-91
   PubMed Web of Science ®Google Scholar
• Breysse N, Amalric M, Salin P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in Parkinsonian rats. J Neurosci 2003;23:8302-9
   PubMed Web of Science ®Google Scholar
• Morin N, Morissette M, Grégoire L, et al. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. Neuropharmacology 2013;73:216-31
   PubMed Web of Science ®Google Scholar
• Coccurello R, Breysse N, Amalric M. Simultaneous blockade of denosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 2004;29:1451-61
   PubMed Web of Science ®Google Scholar
• Turle-Lorenzo N, Breysse N, Baunez C, Amalric M. Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease. Psychopharmacology (Berl) 2005;179:117-27
   PubMed Web of Science ®Google Scholar
• Bashkatova VG, Sudakov SK. Role of metabotropic glutamate receptors in the mechanisms of experimental parkinsonism development. Bull Exp Biol Med 2012;153:655-7
   PubMed Web of Science ®Google Scholar
• Ouattara B, Gasparini F, Morissette M, et al. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J Neurochem 2010;113:715-24
   PubMed Web of Science ®Google Scholar
• Lopez S, Turle-Lorenzo N, Johnston TH, et al. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology 2008;55:483-90
   PubMed Web of Science ®Google Scholar
• Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Pharmacol Exp Ther 2010;333:865-73
   PubMed Web of Science ®Google Scholar
• Levandis G, Bazzini E, Armentero MT, et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson’s disease. Neurobiol Dis 2008;29:161-8
   PubMed Web of Science ®Google Scholar
• Black YD, Xiao D, Pellegrino D, et al. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci Lett 2010;486:161-5
   PubMed Web of Science ®Google Scholar
• Aguirre JA, Kehr J, Yoshitake T, et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res 2005;1033:216-20
   PubMed Web of Science ®Google Scholar
• Masilamoni GJ, Bogenpohl JW, Alagille D, et al. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 2011;134:2057-73
   PubMed Web of Science ®Google Scholar
• Cosford ND, Roppe J, Tehrani L, et al. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEP: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003;13:351-4
   PubMed Web of Science ®Google Scholar
• Morin N, Grégoire L, Morissette M, et al. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 2013;66:355-64
   PubMed Web of Science ®Google Scholar
• Grégoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011;17:270-6
   PubMed Web of Science ®Google Scholar
• Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010;39:352-61
   PubMed Web of Science ®Google Scholar
• Westin JE, Vercammen L, Strome EM, et al. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007;62:800-10
   PubMed Web of Science ®Google Scholar
• Wigal SB, Duong S. Pharmacokinetic evaluation of eltoprazine. Expert Opin Drug Metab Toxicol 2011;7:775-81
   PubMed Web of Science ®Google Scholar
• Fuxe K, Marcellino D, Borroto-Escuela DO, et al. Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 2010;16:e18-42
   PubMed Web of Science ®Google Scholar
• Michalon A, Bruns A, Risterucci C, et al. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile x mice. Biol Psychiatry 2014;75:189-97
   PubMed Web of Science ®Google Scholar
• Gantois I, Pop AS, de Esch CE, et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 2013;239:72-9
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Berry-Kravis E, Hagerman R, et al. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 2014;23:125-34
   PubMed Web of Science ®Google Scholar
• Walles M, Wolf T, Jin Y, et al. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos 2013;41:1626-41
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-50
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Destee A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 2013;28:1838-46
   PubMed Web of Science ®Google Scholar
• Kumar R, Hauser RA, Mostillo J, et al. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson’s disease patients. Int J Neurosci 2013; Epub ahead of print
   Google Scholar
• Elahi B, Phielipp N, Chen R. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta- analysis. Can J Neurol Sci 2012;39:465-72
   PubMed Web of Science ®Google Scholar
• Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81
   PubMed Web of Science ®Google Scholar
• Kubas H, Meyer U, Hechenberger M, et al. Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators. Bioorg Med Chem Lett 2013;23:6370-6
   PubMed Web of Science ®Google Scholar
• Purgert CA, Izumi Y, Jong YJ, et al. Intracellular mGluR5 can mediate synaptic plasticity in the hippocampus. J Neurosci 2014;34:4589-98
   PubMed Web of Science ®Google Scholar
• Ouattara B, Gregoire L, Morissette M, et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2011;32:1286-95
   PubMed Web of Science ®Google Scholar
• Coccurello R, Breysse N, Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats. Neuropsychopharmacology 2004;29:1451-61
   PubMed Web of Science ®Google Scholar
• Battaglia G, Busceti CL, Molinaro G, et al. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. J Neurosci 2004;24:828-35
   PubMed Web of Science ®Google Scholar
• Armentero MT, Fancellu R, Nappi G, et al. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson’s disease. Neurobiol Dis 2006;22:1-9
   PubMed Web of Science ®Google Scholar
• Dekundy A, Gravius A, Hechenberger M, et al. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L -DOPA-induced dyskinesia. J Neural Transm 2011;118:1703-16
   PubMed Web of Science ®Google Scholar